An Abrysvo-Shaped Hole: CDC Panel’s Beyfortus Vote Couldn’t Consider Pfizer’s Pending Vaccine
Executive Summary
The prospect of a game-changing approval of Pfizer’s maternal RSV vaccine hung over CDC committee’s vote on AstraZeneca/Sanofi’s Beyfortus, even though the pending product could not be addressed.
You may also be interested in...
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.
Stock Watch: Pharmaceutical Succession
GLP-1 agonists are creating a stir in obesity management and could possibly prevent non-alcoholic fatty liver disease, with implications for developers of NAFLD treatments. Similarly, another preventative intervention might succeed the treatments for Alzheimer’s disease.
RSV Prevention Implementation Challenges Loom Over Beyfortus’ Regulatory Success
CDC advisory committee unanimously recommends Sanofi/AstraZeneca’s monoclonal antibody for infants in their first respiratory syncytial virus season and high-risk babies and American Indian children in their second RSV season.